Cite
Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.
MLA
Kirzinger, Lukas, et al. “Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.” PloS One, vol. 11, no. 12, Dec. 2016, p. e0168215. EBSCOhost, https://doi.org/10.1371/journal.pone.0168215.
APA
Kirzinger, L., Boy, S., Marienhagen, J., Schuierer, G., Neu, R., Ried, M., Hofmann, H.-S., Wiebe, K., Ströbel, P., May, C., Kleylein-Sohn, J., Baierlein, C., Bogdahn, U., Marx, A., & Schalke, B. (2016). Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PloS One, 11(12), e0168215. https://doi.org/10.1371/journal.pone.0168215
Chicago
Kirzinger, Lukas, Sandra Boy, Jörg Marienhagen, Gerhard Schuierer, Reiner Neu, Michael Ried, Hans-Stefan Hofmann, et al. 2016. “Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.” PloS One 11 (12): e0168215. doi:10.1371/journal.pone.0168215.